X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (78) 78
index medicus (47) 47
humans (46) 46
male (41) 41
female (40) 40
middle aged (39) 39
aged (38) 38
adult (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
chemotherapy (28) 28
camptothecin - analogs & derivatives (22) 22
survival (22) 22
camptothecin - administration & dosage (20) 20
fluorouracil - administration & dosage (20) 20
cancer (19) 19
fluorouracil (19) 19
colorectal neoplasms - drug therapy (18) 18
colorectal neoplasms - pathology (17) 17
disease-free survival (17) 17
treatment outcome (17) 17
cetuximab (16) 16
colorectal cancer (16) 16
metastasis (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
combination (13) 13
irinotecan (13) 13
oxaliplatin (13) 13
analysis (12) 12
antimitotic agents (12) 12
antineoplastic agents (12) 12
bevacizumab (12) 12
leucovorin (12) 12
leucovorin - administration & dosage (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
aged, 80 and over (10) 10
care and treatment (10) 10
colorectal neoplasms - genetics (10) 10
hematology, oncology and palliative medicine (10) 10
kaplan-meier estimate (10) 10
patients (10) 10
survival analysis (10) 10
therapy (10) 10
tumors (10) 10
deoxycytidine - analogs & derivatives (9) 9
mutation (9) 9
young adult (9) 9
cisplatin (8) 8
clinical trials (8) 8
colorectal neoplasms - mortality (8) 8
germany (8) 8
metastatic colorectal cancer (8) 8
neoplasm metastasis (8) 8
open-label (8) 8
organoplatinum compounds - administration & dosage (8) 8
prognosis (8) 8
1st-line treatment (7) 7
adolescent (7) 7
cancer therapies (7) 7
capecitabine (7) 7
deoxycytidine - administration & dosage (7) 7
fluorouracil - therapeutic use (7) 7
hematology (7) 7
kras (7) 7
lung neoplasms - drug therapy (7) 7
metastases (7) 7
multicenter (7) 7
pancreatic neoplasms - drug therapy (7) 7
prospective studies (7) 7
research (7) 7
allergy (6) 6
drug therapy (6) 6
efficacy (6) 6
fluorouracil - analogs & derivatives (6) 6
proportional hazards models (6) 6
trial (6) 6
adenocarcinoma - drug therapy (5) 5
antibodies, monoclonal, humanized - administration & dosage (5) 5
bevacizumab - administration & dosage (5) 5
camptothecin - adverse effects (5) 5
carboplatin - administration & dosage (5) 5
carcinoma (5) 5
cetuximab - administration & dosage (5) 5
colorectal carcinoma (5) 5
fluorouracil - adverse effects (5) 5
metastatic colorectal-cancer (5) 5
neoplasm staging (5) 5
pancreatic cancer (5) 5
phase-iii (5) 5
proto-oncogene proteins p21 - genetics (5) 5
ras proteins - genetics (5) 5
retrospective studies (5) 5
shrinkage (5) 5
abridged index medicus (4) 4
adenocarcinoma (4) 4
antibodies, monoclonal - administration & dosage (4) 4
camptothecin - therapeutic use (4) 4
cancer patients (4) 4
cancer research (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
clinical-trials (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Zeitschrift für Gastroenterologie, ISSN 0044-2771, 08/2013
Sunitinib (S) ist ein oraler Rezeptortyrosinkinase (RTK) Inhibitor vom vaskulären endothelialen Wachstumsfaktor- (VEGFR) und... 
Conference Proceeding
Journal Article
European Journal of Cancer, ISSN 0959-8049, 10/2017, Volume 84, pp. 262 - 269
We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in... 
Cetuximab bevacizumab | FIRE-3 | Survival dynamics | Metastatic colorectal cancer | 1ST-LINE TREATMENT | LEUCOVORIN | OPEN-LABEL | FOLFIRI PLUS BEVACIZUMAB | FLUOROURACIL | CETUXIMAB | ONCOLOGY | RAS MUTATIONS | PHASE-3 TRIAL | IRINOTECAN | KRAS | Bevacizumab - therapeutic use | Proto-Oncogene Proteins p21(ras) - genetics | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cetuximab - therapeutic use | Cetuximab - adverse effects | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Leucovorin - therapeutic use | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Camptothecin - therapeutic use | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Biomarkers, Tumor - genetics | Mutation | Colorectal Neoplasms - pathology | Clinical trials | Metastasis | Analysis | Colorectal cancer | Evaluation | Medical treatment | Colorectal carcinoma | Patients | Survival | Bevacizumab | Metastases | Confidence intervals | Survival analysis | Short courses | Randomization | Motivation | Kinetics | Cancer | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2012, Volume 23, Issue 7, pp. 1693 - 1699
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 79, pp. 50 - 60
Abstract Background RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil,... 
Hematology, Oncology and Palliative Medicine | BRAF | Cetuximab | RAS | Colorectal cancer | Bevacizumab | PHASE-III | OPEN-LABEL | FLUOROURACIL | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | THERAPY | ONCOLOGY | POOLED ANALYSIS | IRINOTECAN | KRAS | SUBGROUP ANALYSIS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - administration & dosage | Liver Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Liver Neoplasms - drug therapy | Exons - genetics | Male | Treatment Outcome | Mutation - genetics | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Retrospective Studies | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Viral antibodies | Antimitotic agents | Epidermal growth factor | Gene mutations | Analysis | Antibodies | Genetic aspects | Metastasis | Antineoplastic agents | Epidermal growth factor receptors | 5-Fluorouracil | Colorectal carcinoma | Clinical trials | Shrinkage | Paraffin | Patients | Survival | Subgroups | Metastases | Irinotecan | Mutation | Vascular endothelial growth factor | Tumors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1065 - 1075
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2013, Volume 108, Issue 2, pp. 469 - 476
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 94, pp. 95 - 103
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 7, pp. 679 - 687
Journal Article